Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Acute Myeloid Leukemia
100%
Venetoclax
81%
Newly Diagnosed
36%
Relapsed or Refractory Acute Myeloid Leukemia
26%
Hypomethylating Agents
24%
Overall Survival
24%
Intensive Chemotherapy
23%
Decitabine
23%
Complete Remission
18%
Relapsed or Refractory
16%
Chronic Myeloid Leukemia
13%
Myelodysplastic Syndrome
12%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
12%
Leukemia
11%
Phase II Trial
11%
Phase II Study
10%
Azacitidine
10%
FLAG-Ida
10%
Event-free Survival
10%
Minimal Residual Disease
9%
Isocitrate Dehydrogenase 1 (IDH1)
9%
Median Overall Survival
9%
High Risk
8%
Overall Response Rate
8%
Tumor Protein p53 (TP53)
8%
Blast Phase
7%
Induction Chemotherapy
7%
Improved Outcomes
6%
Unfit Patients
6%
Older Patients
6%
Treatment Strategy
6%
B-cell Lymphoma 2 (Bcl-2)
6%
Confidence Interval
5%
Propensity Score Analysis
5%
Secondary Acute Myeloid Leukemia (sAML)
5%
Frontline Treatment
5%
FLT3 mutation
5%
FLT3 Inhibitor
5%
Enasidenib
5%
Older Adults
5%
Myeloid Blasts
5%
Cedazuridine
5%
Gemtuzumab Ozogamicin
5%
RAS mutant
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
86%
Venetoclax
66%
Chemotherapy
29%
Overall Survival
25%
Decitabine
19%
Remission
16%
Leukemia
13%
Myelodysplastic Syndrome
11%
Azacitidine
10%
Minimal Residual Disease
9%
Protein Tyrosine Kinase Inhibitor
8%
Chronic Myeloid Leukemia
8%
Diseases
8%
Malignant Neoplasm
7%
Myeloid Leukemia
7%
Secondary Acute Myeloid Leukemia
6%
Event Free Survival
6%
Adverse Event
6%
Enasidenib
5%
Clinical Trial
5%
Philadelphia 1 Chromosome
5%
Acute Lymphoblastic Leukemia
5%
Isocitrate Dehydrogenase
5%
Medicine and Dentistry
Acute Myeloid Leukemia
87%
Venetoclax
68%
Overall Survival
32%
Decitabine
21%
Hypomethylating Agent
21%
Cancer
9%
Minimal Residual Disease
9%
Leukemia
9%
Event Free Survival
8%
Malignant Neoplasm
8%
Tyrosine-Kinase Inhibitor
8%
Myelodysplastic Syndrome
7%
Induction Chemotherapy
7%
Neoplasm
7%
Myeloid Leukemia
6%
Azacitidine
6%
Adverse Event
6%
Acute Myelogenous Leukemia
6%
Allogeneic Stem Cell Transplantation
5%
Secondary Acute Myeloid Leukemia
5%
Chronic Myelogenous Leukemia
5%
Infection
5%
Meta-Analysis
5%
Cedazuridine
5%
Pediatrics
5%